Starting treatment: latest news

Starting treatment resources

Starting treatment features

Starting treatment in your own words

Starting treatment news from aidsmap

  • Restoring and maintaining a high CD4 count possible for vast majority of people living with HIV in France

    A large French study has shown that the vast majority of people living with HIV who started treatment since 2000 in a national cohort achieved a CD4 cell count in the normal range within three to four years of ...

    12 November 2014 | Alain Volny-Anne
  • What are the barriers that could stop HIV treatment becoming HIV prevention?

    One of the key strategies involved in trying to bring an end to the HIV epidemic is to increase the proportion of HIV-positive people on antiretroviral therapy (ART), to the point where suppressing their viral load starts to ...

    12 November 2014 | Gus Cairns
  • Once-daily dolutegravir superior to darunavir/ritonavir in 96-week follow-up

    Treatment with a triple antiretroviral combination containing once-daily integrase inhibitor dolutegravir (Tivicay) is superior to the ritonavir-boosted protease inhibitor darunavir (Prezista) over 96 weeks of follow-up, Jean-Michel Molina of the Hôpital Saint Louis, Paris, reported at the HIV Drug ...

    10 November 2014 | Alain Volny-Anne
  • Doravirine works as well as efavirenz with fewer CNS side-effects

    Once-daily doravirine (MK-1439), an experimental NNRTI, demonstrated viral suppression similar to that of efavirenz at 48 weeks, and the dose selected for further development was associated with fewer central nervous system (CNS) side-effects, researchers reported last week at the HIV ...

    10 November 2014 | Liz Highleyman
  • Do emtricitabine and lamivudine have similar virological efficacy when used in first-line HIV therapy?

    First-line antiretroviral regimens containing emtricitabine have superior virological efficacy to combinations containing lamivudine when combined with tenofovir and either nevirapine or efavirenz, Dutch investigators report in the online edition of Clinical Infectious Diseases.The findings were also presented by Casper Rokx ...

    03 November 2014 | Michael Carter
  • NNRTIs and protease inhibitors both good for first ART, channelling affects choices

    Non-nucleoside reverse transcriptase inhibitors (NNRTIs) and boosted protease inhibitors work equally well for people starting HIV treatment for the first time, with similar viral suppression, CD4 cell gains, and disease progression, according to a large meta-analysis presented at IDWeek 2014 earlier this month in Philadelphia, United States. ...

    22 October 2014 | Liz Highleyman
  • South African women living with HIV subtype C experience rapid CD4 cell loss

    A third of women living with HIV subtype C have a fall in their CD4 count to below 350 cells/mm3 within a year of seroconversion, investigators report in the online edition of Clinical Infectious Diseases. The World Health Organization ...

    05 August 2014 | Michael Carter
  • Efavirenz use not linked to neurocognitive impairment

    People who use antiretroviral regimens containing efavirenz (Sustiva or Stocrin, also in the Atripla coformulation) were not at higher risk for impaired neurocognitive function, either overall or when looking at specific functional domains, researchers reported on Thursday at the 20th ...

    25 July 2014 | Liz Highleyman
  • Dolutegravir demonstrates good efficacy despite resistance

    Antiretroviral regimens containing the recently approved HIV integrase inhibitor dolutegravir (Tivicay) demonstrated high rates of viral suppression even in treatment-experienced people who had virus with resistance to NRTIs. Among people starting treatment for the first time, no resistance was ...

    24 July 2014 | Liz Highleyman
  • Could HIV treatment mean safer sex?

    A meta-analysis of every study that has looked at the sexual behaviour of people after starting HIV treatment has found not a single instance of so-called ‘risk compensation’ – the idea that if people start taking HIV treatment ...

    24 July 2014 | Gus Cairns
More news

Starting treatment news selected from other sources

  • NNRTI + 3 NRTIs may be strong first regimen in UKIreland children

    Children starting antiretroviral therapy (ART) with a nonnucleoside (NNRTI) plus 3 nucleosides (NRTIs) had the lowest 2-year virologic failure rate in a study of 997 children in the United Kingdom and Ireland. Five-year toxicity rates were similar with the NNRTI and protease inhibitor (PI) regimens studied.

    6 hours ago | International AIDS Society
  • Early Initiation of Combo Antiretrovirals Gaining Support

    Evidence continues to support the initiation of combined antiretroviral therapy soon after HIV infection, researchers report. In fact, the likelihood of the CD4/CD8 ratio normalizing was almost three times greater if antiretroviral therapy was initiated within 6 months of HIV infection than if it was delayed for more than 6 months, according to John Thornhill, MD, from Imperial College London in the United Kingdom, and his team.

    07 November 2014 | Medscape (requires registration)
  • Effective treatments available for HIV patients not eligible for efavirenz regimens

    HIV drug regimens that do not include efavirenz are effective as first-line antiretroviral therapy, a new American clinical trial found. The finding is important for patients who are not eligible for treatment with efavirenz, including women considering becoming pregnant and patients with a history of severe psychiatric disorders.

    07 October 2014 | Science Daily
  • Why I Refused, Then Later Embraced, HIV Treatment

    "On good days, adhering to my pill is a positive affirmation of my life, an exercise in self-love. On bad days, it's just a pill I need to swallow, not terribly bitter but as mildly annoying as having to shave or tie my shoelaces every day. It's yet another thing to add to my list of things, but I do it anyway." Josh Kruger on his ambiguous relationship to HIV treatment.

    01 October 2014 |
  • Uganda: Aids Patients Reject Bitter ARVs

    The Uganda Coalition for Access to Essential Medicine (UCAEM) has asked government to withdraw and cease use of non-film coated tenofovir and lamivudine, dubbing the drug combination as notoriously bitter. "People living with HIV will more likely stop taking treatment than use this medicine," said Margaret Happy, the advocacy officer of the International Community of Women in East Africa (ICWEA).

    10 September 2014 |
  • Men Who Have Sex With Men Getting Treatment Sooner

    Long-term trends indicate that European men who have sex with men are seeking treatment for HIV at earlier stages of their disease, researchers reported here.

    25 July 2014 | MedPage Today
  • Option B+: In obstacle courses to lifelong antiretroviral treatment, hurdles are higher for pregnant women, study says

    Work conflicts, hidden HIV status, and bad treatment by staff are among the hurdles keeping women living with HIV from continuing antiretroviral treatment for life following childbirth, according to a article published last month ahead of print in the Journal of Acquired Immune Deficiency Syndromes.

    09 July 2014 | Science Speaks
  • New ARV prescribing guidelines for London (2014)

    The guidelines are the result of a therapeutic tender, which encourages drug manufacturers to offer volume discounts for different stages of the treatment pathway, for example, for preferred use in first-line, second-line and multiple resistant treatment.

    01 July 2014 | HIV i-Base
  • Dolutegravir in HIV-1 infection: Added benefit in adult patients

    The German Institute for Quality and Efficiency in Health Care (IQWiG) has determined that the new integrase inhibitor drug dolutegravir (Tivicay ®) is of considerable added benefit to treatment-naive patients in comparison with current first-line therapies, and some added benefit to patients who already need to take an integrase inhibitor.

    19 June 2014 | Science Daily
  • First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily formulation of raltegravir (Isentress)

    Merck (MSD) today announced that the first patient has been enrolled in the company’s global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a once-daily investigational formulation of ISENTRESS® (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-naïve HIV-1-infected adults. Raltegravir combines high potency with low toxicity but its more widespread use has been held back by its needing to be taken twice a day.

    06 June 2014 | Merck
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.